Licensing shouldn’t be the hardest part of genomic innovation.
Benson Hill’s portfolio of CRISPR Cms1 nucleases represents a major expansion of the gene editing toolbox, providing an alternative solution for researchers and industry. This patented portfolio together with a streamlined partnership model provides a clear path from development to commercialization.
Gene editing means innovative crops and ingredients for our food and agriculture systems, and cost and time savings for your research and development program.
Unlock our Gene Editing Decision Tree and other gene editing resources to see what’s possible with Benson Hill’s CRISPR Cms1.